VGT 1849A
Alternative Names: VGT-1849ALatest Information Update: 10 Feb 2025
At a glance
- Originator Vanda Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Gene silencing; Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Polycythaemia vera